

**INFORMED CONSENT FOR MEDICATION**

**Dosage and / or Side Effect information last revised on 08/18/2022**

Completion of this form is voluntary. If informed consent is not given, the medication cannot be administered without a court order unless in an emergency.

This consent is maintained in the client's record and is accessible to authorized users.

Name – Patient / Client (Last, First MI)		ID Number	Living Unit	Date of Birth
Name – Individual Preparing This Form		Name – Staff Contact		Name / Telephone Number – Institution

MEDICATION CATEGORY	MEDICATION	RECOMMENDED DAILY TOTAL DOSAGE RANGE	ANTICIPATED DOSAGE RANGE
Antihistamine (sedative, antianxiety)	<ul style="list-style-type: none"> <li>▪ Atarax (hydroxyzine hydrochloride)</li> <li>▪ Hydroxyzine intramuscular injection</li> </ul>	<ul style="list-style-type: none"> <li>▪ Oral: 25 mg – 400 mg</li> <li>▪ Injectable: 25 mg – 400 mg</li> </ul>	

The anticipated dosage range is to be individualized, may be above or below the recommended range but no medication will be administered without your informed and written consent.

Recommended daily total dosage range of manufacturer, as stated in *Physician's Desk Reference* (PDR) or another standard reference.

This medication will be administered  Orally  Injection  Other – Specify:

**1. Reason for Use of Psychotropic Medication and Benefits Expected (note if this is 'Off-Label' Use)**

Include DSM-5 diagnosis or the diagnostic impression ("working hypothesis.")

**2. Alternative mode(s) of treatment other than OR in addition to medications include**

Note: Some of these would be applicable only in an inpatient environment.

- |   |   |
|---|---|
| <input type="checkbox"/> Environment and/or staff changes           | <input type="checkbox"/> Rehabilitation treatments/therapy (OT, PT, AT)   |
| <input type="checkbox"/> Positive redirection and staff interaction | <input type="checkbox"/> Treatment programs and approaches (habilitation) |
| <input type="checkbox"/> Individual and/or group therapy            | <input type="checkbox"/> Use of behavior intervention techniques          |

**Other Alternatives:**

**3. Probable consequences of NOT receiving the proposed medication are**

Impairment of  Work Activities  Family Relationships  Social Functioning

**Possible increase in symptoms leading to potential**

- |  |  |
|--|--|
| <input type="checkbox"/> Use of seclusion or restraint                   | <input type="checkbox"/> Limits on recreation and leisure activities |
| <input type="checkbox"/> Limits on access to possessions                 | <input type="checkbox"/> Intervention of law enforcement authorities |
| <input type="checkbox"/> Limits on personal freedoms                     | <input type="checkbox"/> Risk of harm to self or others              |
| <input type="checkbox"/> Limit participation in treatment and activities |  |

**Other Consequences:**

**Note:** These consequences may vary depending upon whether or not the individual is in an inpatient setting. It is also possible that in unusual situations, little or no adverse consequences may occur if the medications are not administered.

See Page 2

Client Initial \_\_\_\_\_ Date \_\_\_\_\_

4. Possible side effects, warnings, and cautions associated with this medication are listed below. This is not an all-inclusive list but is representative of items of potential clinical significance to you. For more information on this medication, you may consult further with your physician or refer to a standard text, such as the PDR. As part of monitoring some of these potential side effects, your physician may order laboratory or other tests. The treatment team will closely monitor individuals who are unable to readily communicate side effects in order to enhance care and treatment.

Continued – Possible side effects, warnings, and cautions associated with this medication.

**Most Common Side Effects:** drowsiness; dry mouth, nose, or throat.

**Less Common Side Effects:** feeling clumsy, confused, or sleepy; congestion; constipation; blurry vision; changes in vision; difficult or painful urination; fast, pounding heartbeat; increased sweating; indigestion; loss or gain of appetite; joint pain; muscle aching or cramping; muscle stiffness; uncontrollable movement of the muscles; nausea; ringing or buzzing in ears; runny nose; stomach discomfort, or pain; tremor; unusual excitement, nervousness, restlessness, or irritability.

**Rare Side Effects:** Although rare, please contact your doctor as soon as possible if any of the following side effects occur: severe abdominal or stomach pain; clay-colored stools or dark urine; severe diarrhea; difficulty swallowing; dizziness; fast or irregular heartbeat; fever; severe headache; hives; itching; prickly sensations; puffiness or swelling of the eyes, face, lips or tongue; redness of skin; seizures; shortness of breath; skin rash; tightness in chest; wheezing; severely sore throat; unusual bleeding or bruising; hallucinations.

### Caution

- **Driving and operating heavy machinery**

Using hydroxyzine with other central nervous system depressants such as narcotics, non-narcotic analgesics, barbiturates, or alcohol may cause the worsening or onset of drowsiness. Please tell your doctor if you are taking any of these medications or regularly drink alcohol. Using these drugs in combination or alone may make it dangerous to drive a car, operate heavy machinery, or participate in anything else that requires mental alertness. Be sure you know how this medication affects you before participating in these activities.

- **Beers Criteria: Use of this medication in older adults**

Because older adults are more likely to have decreased renal function, this medication should be avoided if possible. If not possible, try starting at the lower end of the dosing range. Sedating drugs may cause confusion and over sedation in the elderly; elderly patients generally should be started on low doses of hydroxyzine and observed closely. Older adults who experience increasing dizziness, drowsiness, or confusion, should contact their doctor to discuss these symptoms.

- **Skin rash**

If you experience a new rash or abnormal bumps on the skin, especially with a fever, it is recommended to stop taking hydroxyzine and to contact your doctor as soon as possible. This is a rare side effect of this drug.

- **Cardiovascular risk: QT Prolongation**

Individuals who have been diagnosed with a prolonged QT interval, who have a condition called Torsades de Pointes, or who have other cardiovascular diseases should inform their doctor of this condition before starting hydroxyzine. Hydroxyzine can affect the activity of the heart, so it is always best to check with your doctor before taking this medication.

- **Glaucoma**

Individuals who have been diagnosed with glaucoma should inform their doctor of this condition before starting hydroxyzine. This medication may make glaucoma worse in some individuals, such as those with narrow-angle glaucoma.

- **Benign Prostatic Hyperplasia (BPH)**

Individuals who have been diagnosed with an enlarged prostate, or difficulty with urination should inform their doctor of this condition before starting hydroxyzine. This medication may make BPH or difficulty with urination worse in some individuals.

- **Respiratory conditions**

Individuals who have been diagnosed with asthma, COPD, or other conditions that affect respiratory function should inform their doctor of this condition before starting hydroxyzine. This medication may make conditions such as these worse in some individuals.

See standard reference text for an all-inclusive list of side effects.

**By my signature below, I GIVE consent for the named medication on Page 1 and anticipated dosage range. My signature also indicates that I understand the following:**

1. I can refuse to give consent or can withdraw my consent at any time with written notification to the institution director or designee. This will not affect my right to change my decision at a later date. If I withdraw consent after a medication is started, I realize that the medication may not be discontinued immediately. Rather, it will be tapered as rapidly as medically safe and then discontinued so as to prevent an adverse medical consequence, such as seizures, due to rapid medication withdrawal.
2. Questions regarding this medication can be discussed with the Interdisciplinary Team, including the physician. The staff contact person can assist in making any necessary arrangements.
3. Questions regarding any behavior support plan or behavior intervention plan, which correspond with the use of the medication, can be directed to the client's social worker, case manager, or psychologist.
4. I have the right to request a review at any time of my record, pursuant to § 51.30(4)(d) or § 51.30(5)(b).
5. I have a legal right to file a complaint if I feel that client rights have been inappropriately restricted. The client's social worker, case manager, or agency/facility client rights specialist may be contacted for assistance.
6. My consent permits the dose to be changed within the **anticipated dosage range** without signing another consent.
7. I understand the reasons for the use of the medication, its potential risks and benefits, other alternative treatment(s), and the probable consequences that may occur if the proposed medication is not given. I have been given adequate time to study the information and find the information to be specific, accurate, and complete.
8. This medication consent is for a period effective immediately and not to exceed fifteen (15) months from the date of my signature. The need for and continued use of this medication will be reviewed at least quarterly by the Interdisciplinary Team. The goal, on behalf of the client, will be to arrive at and maintain the client at the minimum effective dose.

**SIGNATURES**

**DATE SIGNED**

Client – If Presumed Competent to Consent/Parent of Minor/Guardian (POA-HC)	Relationship to Client <input type="checkbox"/> Self <input type="checkbox"/> Parent <input type="checkbox"/> Guardian (POA-HC)	
Staff Present at Oral Discussion	Title	

Client / Parent of Minor / Guardian (POA-HC) Comments

**As parent/guardian (POA-HC) was not available for signature, he/she was verbally informed of the information in this consent.**

**Verbal Consent**

Obtained by – PRINT – Staff Name	Date Obtained	Written Consent Received <input type="checkbox"/> Yes <input type="checkbox"/> No
Obtained from – PRINT – Parent / Guardian (POA-HC) Name	Date Expires	Date Received